← All trials
NCT04505397
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 13, 2020
- Primary completion
- Oct 18, 2021
- Completion date
- Mar 31, 2022
- First posted
- Aug 10, 2020
- Last posted
- Sep 7, 2020
- Enrollment
- 98
- Arms / groups
- 14 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ArvelleLead sponsor
- Spaulding Clinical Research Inc.Collaborator
- CovanceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.